{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nepafenac",
    "query": {
      "intervention": "Nepafenac"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 22,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nepafenac&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T19:02:04.012Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02515045",
      "title": "Dropless vs. Standard Drops Contralateral Eye Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "TriMoxiVanc",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin HCl 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Ilevro",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone acetate 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Carolina Eyecare Physicians, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 59,
      "start_date": "2015-01",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2018-02-23",
      "last_synced_at": "2026-09-07T19:02:04.012Z",
      "location_count": 4,
      "location_summary": "Bloomington, Minnesota • Stillwater, Minnesota • Garden City, New York + 1 more",
      "locations": [
        {
          "city": "Bloomington",
          "state": "Minnesota"
        },
        {
          "city": "Stillwater",
          "state": "Minnesota"
        },
        {
          "city": "Garden City",
          "state": "New York"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02515045"
    },
    {
      "nct_id": "NCT00377546",
      "title": "Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Vitrectomy"
      ],
      "interventions": [
        {
          "name": "Nepafenac",
          "type": "DRUG"
        },
        {
          "name": "Ketorolac LS, Bromfenac",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Innovative Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-09-25",
      "last_synced_at": "2026-09-07T19:02:04.012Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00377546"
    },
    {
      "nct_id": "NCT07276802",
      "title": "The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Post Cataract Surgery"
      ],
      "interventions": [
        {
          "name": "Triamcinolone (Optional)",
          "type": "DRUG"
        },
        {
          "name": "control group",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Research Insight LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2026-04-01",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-09-07T19:02:04.012Z",
      "location_count": 1,
      "location_summary": "Laguna Hills, California",
      "locations": [
        {
          "city": "Laguna Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07276802"
    },
    {
      "nct_id": "NCT02752646",
      "title": "Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "nepafenac 0.3%",
          "type": "DRUG"
        },
        {
          "name": "ketorolac",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MDbackline, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 200,
      "start_date": "2016-04",
      "completion_date": "2017-03-01",
      "has_results": false,
      "last_update_posted_date": "2017-03-07",
      "last_synced_at": "2026-09-07T19:02:04.012Z",
      "location_count": 2,
      "location_summary": "Laguna Hills, California • Edgewood, Kentucky",
      "locations": [
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Edgewood",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02752646"
    },
    {
      "nct_id": "NCT03499873",
      "title": "Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Nepafenac 0.3% Oph Susp",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        },
        {
          "name": "Nepafenac 0.3% Oph Susp (reference)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 448,
      "start_date": "2018-03-28",
      "completion_date": "2018-12-18",
      "has_results": true,
      "last_update_posted_date": "2021-02-16",
      "last_synced_at": "2026-09-07T19:02:04.012Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03499873"
    },
    {
      "nct_id": "NCT00828477",
      "title": "Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Intraocular Pressure"
      ],
      "interventions": [
        {
          "name": "Xibrom",
          "type": "DRUG"
        },
        {
          "name": "Nevanac",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bp Consulting, Inc",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2009-01",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2009-06-10",
      "last_synced_at": "2026-09-07T19:02:04.012Z",
      "location_count": 1,
      "location_summary": "3340 6 Mile Rd Livonia, Michigan",
      "locations": [
        {
          "city": "3340 6 Mile Rd Livonia",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00828477"
    },
    {
      "nct_id": "NCT00330798",
      "title": "A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Photorefractive Keratectomy"
      ],
      "interventions": [
        {
          "name": "nepafenac 0.1%",
          "type": "DRUG"
        },
        {
          "name": "ketorolac 0.4%",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2006-02",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2016-11-18",
      "last_synced_at": "2026-09-07T19:02:04.012Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00330798"
    },
    {
      "nct_id": "NCT00407017",
      "title": "Therapeutic Variables in Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cataract Surgery"
      ],
      "interventions": [
        {
          "name": "Gatifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Ketorolac LS",
          "type": "DRUG"
        },
        {
          "name": "Pred Forte",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Nepafenac",
          "type": "DRUG"
        },
        {
          "name": "EconoPred Plus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Innovative Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-08-21",
      "last_synced_at": "2026-09-07T19:02:04.012Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00407017"
    },
    {
      "nct_id": "NCT01109173",
      "title": "Confirmatory Study Nepafenac 0.3%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Nepafenac Ophthalmic Suspension, 0.3%",
          "type": "DRUG"
        },
        {
          "name": "Nepafenac Ophthalmic Suspension, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Nepafenac Ophthalmic Suspension 0.3% Vehicle",
          "type": "OTHER"
        },
        {
          "name": "NEVANAC Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2120,
      "start_date": "2010-06",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2012-11-30",
      "last_synced_at": "2026-09-07T19:02:04.012Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01109173"
    },
    {
      "nct_id": "NCT01847638",
      "title": "Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cataract",
        "Retinal Edema",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "Prolensa (bromfenac 0.07%)",
          "type": "DRUG"
        },
        {
          "name": "Ilevro (nepafenac 0.3%)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melissa Toyos",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2013-04-01",
      "completion_date": "2018-08-23",
      "has_results": true,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-09-07T19:02:04.012Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01847638"
    }
  ]
}